ArticleScientific reports2025
microRNA-576-5p ameliorates dexamethasone-induced BMSC injury by suppressing ANXA2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bioactive magnesium alloy scaffold integrated with BMSCs-Loaded 3D microspheres synergistically promotes femoral head osteonecrosis repair by improving the osteogenic-angiogenic microenvironment.Bioactive materials · 2026Article
- Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dysfunction of Bone Marrow Derived Mesenchymal Stem Cells (BMSCs) induced by glucocorticoids has been identified as a key pathological mechanism of steroid-induced osteonecrosis of the femoral head (SONFH). Consequently, restoring the function of BMSCs is a vital strategy for treating SONFH. This study aimed to investigate the role of microRNA-576-5p (miR-576-5p) and Annexin A2 (ANXA2) in SONFH and dexamethasone (DEX) cultured BMSCs, expecting to seek new therapeutic strategies for SONFH. RNA and protein samples were extracted from the bone tissue of femoral heads and DEX treated BMSCs to verify the potential relationship among miR-576-5p, ANXA2 and SONFH. Then, the interaction between miR-576-5p and ANXA2 mRNA was investigated through dual luciferase reporter assays. Finally, BMSC proliferation, apoptosis, mineralization, and its capacity for pro-osteoclastogenesis after increasing miR-576-5p levels or reducing ANXA2 expression were detected with 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.